Novartis’ next blockbuster? New drug cuts heart failure death rate a stunning 20 percent
Novartis could be on the verge of its next blockbuster. The Swiss pharma giant’s new heart failure drug could prove to replace the current standard of therapy, the company announced Saturday. A wide-spanning heart failure study found that Novartis’ drug candidate LCZ696 cut cardiovascular deaths by 20 percent when compared to ACE-inhibitors, which have been the go-to heart failure treatment […]